Modafinil: A Review of Neurochemical Actions and Effects on Cognition
The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. Pre-clinical studies of modafinil suggest a complex profile of neurochemical and behavioral effects, distinct from those of amphetamine. In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/hyperactivity disorder, and schizophrenia. Cognitive dysfunction may be a particularly important emerging treatment target for modafinil, across these and other neuropsychiatric disorders. We aimed to comprehensively review the empirical literature on neurochemical actions of modafinil, and effects on cognition in animal models, healthy adult humans, and clinical populations. We searched PubMed with the search term 'modafinil' and reviewed all English-language articles for neurochemical, neurophysiological, cognitive, or information-processing experimental measures. We additionally summarized the pharmacokinetic profile of modafinil and clinical efficacy in psychiatric patients. Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action. In addition, modafinil (at well-tolerated doses) improves function in several cognitive domains, including workin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, side effects of alpha agonists like guanfacine and clonidine include high prevalence of somnolence or sedating effects,168,169”
From Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome (2023) · cites this paper as [168]
In the citing paper
“Modafinil, which is approved by the US Food and Drug Administration for the treatment of narcolepsy and its associated daytime sleepiness [59], is a logical candidate to address the hypoactive/sleepy aspects of CDS.”
Citations
Cites
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472 · cited 7×
“Importantly, modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described in the Aston…”
BackgroundMethodResultInfluentialNarcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 3×
“m Fos in orexin neurons in perfornical area 150 mg/kg i.p. Immunohisto-chemistry Mice Chemelli et al, 1999 75 mg/kg i.p. Immunohisto-chemistry Rat Scammell et al, 2000 No binding to orexin-1 receptor IC50 410mM 125I-human-orexin B displacement Transfected Chinese Hamster Ovary cells Wieland et al,…”
BackgroundAston-Jones, G., & Bloom, F. (1981) · The Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00876.1981 · Cited by 1,960 · cited 1×
“It appears also that when levels of tonic LC activity are minimal, such as during sleep, grooming, and eating, that phasic responses are also less robust (Aston-Jones and Bloom, 1981).”
BackgroundTask-evoked pupillary responses, processing load, and the structure of processing resources.
Beatty, J. (1982) · Psychological Bulletin · doi:10.1037/0033-2909.91.2.276 · Cited by 1,959 · cited 1×
“…modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described…”
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 15×
“Inhibition of DA cell firing in VTA/SN; blocked by Sulpiride 10mM but not by Prazosin 20 mM Extracellular recording Rat brain slice Korotkova et al, 2006 Hyperpolarization of VTA neurons, blocked by Sulpiride 10mM 20–50mM Whole-cell patch clamp Isolated VTA neurons No effect on mesencephalic DA neuron activity 128 mg/…”
BackgroundInfluentialDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
The role of histamine and the tuberomamillary nucleus in the nervous system
Haas, H., & Panula, P. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1034 · Cited by 929 · cited 5×
“Thalamic NET occupancy: 16, 44% 5, 8 mg/kg i.v. PET with [11C]MeNER Rhesus monkey Madras et al, 2006 NET binding IC50¼ 35.6mM [3H] NE Human Embryo Kidney No effect on pontine NE neuron activity 128 mg/kg i.p. Single-unit recording Rat (anesthetized) Akaoka et al, 1991 Extracellular NE: m in PFC, medial hypothalamus 12…”
BackgroundInfluentialDopaminergic Role in Stimulant-Induced Wakefulness
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01787.2001 · Cited by 769 · cited 7×
“…extracellular DA levels (measured by microdialysis) that are increased significantly in the rat prefrontal cortex (PFC) (de Saint Hilaire et al, 2001), and in the caudate nucleus of narcoleptic dogs (Wisor et al, 2001), although only minimally in the rat hypothalamus (de Saint Hilaire et al, 2001).”
BackgroundInfluentialThe role of locus coeruleus in the regulation of cognitive performance
Usher, M., Cohen, J. D., Servan-Schreiber, D., Rajkowski, J., & Aston-Jones, G. (1999) · Science · doi:10.1126/science.283.5401.549 · Cited by 715
Research works printed but not linked: 1
- Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC et al (1999b). A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 39: 30–40. · DOI · Paper page
Cited by
Inhibition and impulsivity: behavioral and neural basis of response control
Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921
Towards responsible use of cognitive-enhancing drugs by the healthy
Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., & Farah, M. J. (2008) · Nature · doi:10.1038/456702a · Cited by 862
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review
Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.04.002 · Cited by 576
Eagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548
Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 529
“Modafinil may enhance cognition and is used off-label for the treatment of cognitive dysfunction in some psychiatric disorders (ie, schizophrenia, attention-deficit/ hyperactivity disorder [ADHD]).(1) Moreover, modafinil is increasingly being diverted for nonmedical use by healthy individuals with the expectation that…”
BackgroundCognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
“…2005; Daniel et al, 1991), and more recent evidence that modafinil improves PFC-dependent cognition in schizophrenia patients (Turner et al, 2004; for a review, see Minzenberg and Carter, 2008a), which may be a function of modulation of locus coeruleus neuronal activity (Minzenberg et al, 2008b).”
BackgroundSelf-citationConnolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
“Although classified as a type of stimulant, modafinil is a novel wakefulness-promoting agent thought to act primarily on dopamine and norepinephrine neurotransmission with secondary elevations of serotonin, glutamate and histamine, as well as effects on orexinergic transmission.([59]) In addition to its indicated use…”
Smith, M. E., & Farah, M. J. (2011) · Psychological Bulletin · doi:10.1037/a0023825 · Cited by 440
“Originally marketed as a therapy for narcolepsy, it is widely used off label for other purposes (Vastag, 2004), and a limited literature on its cognitive effects suggests some promise as a cognitive enhancer for normal healthy people (see Minzenberg & Carter, 2008, for a review).”
Neurocognitive Mechanisms in Depression: Implications for Treatment
Clark, L., Chamberlain, S. R., & Sahakian, B. J. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125618 · Cited by 446
Approved and Investigational Uses of Modafinil: An Evidence-Based Review
Kumar, R. (2008) · Drugs · doi:10.2165/00003495-200868130-00003 · Cited by 415
Why gamblers fail to win: A review of cognitive and neuroimaging findings in pathological gambling
van Holst, R. J., van den Brink, W., Veltman, D. J., & Goudriaan, A. E. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.007 · Cited by 372
Ranganath, C. (2010) · Hippocampus · doi:10.1002/hipo.20852 · Cited by 375
“We found that hippocampal activation was significantly increased during the memory delay, as might be expected if this region was involved in maintenance of each novel face.vii In a second experiment, we replicated our previous finding of hippocampal activation during maintenance of novel faces in…”
ResultThe molecular and cellular biology of enhanced cognition
Lee, Y.-S., & Silva, A. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2572 · Cited by 361
Cognitive enhancement as a treatment for drug addictions
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.021 · Cited by 298
“Modafinil, is a weak inhibitor of DAT and NET and has additional effects on the brain GABA, glutamate, and orexin (Minzenberg and Carter, 2008).”
BackgroundCognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies
Murrough, J. W., Iacoviello, B., Neumeister, A., Charney, D. S., & Iosifescu, D. V. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.06.006 · Cited by 307
“Therefore, studies have begun to examine the clinical impact of pharmacological agents targeting cognitive impairments in depression and other psychiatric disorders (Chamberlain, Muller, Robbins, & Sahakian, 2006; Minzenberg & Carter, 2008).”
Recent theoretical, neural, and clinical advances in sustained attention research
Fortenbaugh, F. C., DeGutis, J., & Esterman, M. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13318 · Cited by 271
The solute carrier 6 family of transporters
Bröer, S., & Gether, U. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01975.x · Cited by 269
“Accordingly, modafinil might also be a promising therapeutic agent for cocaine addiction (Dackis et al., 2005; Hart et al., 2008; Minzenberg and Carter, 2008).”
BackgroundThe kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders
Stone, T. W., & Darlington, L. G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12230 · Cited by 271
“Several other neurotransmitter systems, such as those releasing histamine and neuropeptides have been implicated in cognitive performance or its modification by drugs (Minzenberg and Carter, 2008).”
BackgroundThe Cognitive Neuroscience of Memory Function and Dysfunction in Schizophrenia
Ranganath, C., Minzenberg, M. J., & Ragland, J. D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.011 · Cited by 263
Self-citationSchmidt, H. D., & Pierce, R. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05144.x · Cited by 254
Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation
Wood, S., Sage, J. R., Shuman, T., & Anagnostaras, S. G. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007054 · Cited by 259
Cognitive enhancement by drugs in health and disease
Husain, M., & Mehta, M. A. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2010.11.002 · Cited by 241
Dopaminergic D1and D2Receptors Are Essential for the Arousal Effect of Modafinil
Qu, W.-M., Huang, Z.-L., Xu, X.-H., Matsumoto, N., & Urade, Y. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1819-08.2008 · Cited by 230
Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review
Battleday, R. M., & Brem, A.-K. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.028 · Cited by 215
The treatment of cognitive impairment in schizophrenia
Goff, D. C., Hill, M., & Barch, D. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.009 · Cited by 194
“It has been reported to increase activity of catecholamines, glutamate, serotonin, GABA, orexin and histamine, and to enhance cognitive functioning in several models (Minzenberg and Carter, 2008).”
The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
Heal, D. J., Cheetham, S. C., & Smith, S. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.020 · Cited by 198
“Minzenberg and Carter (2008) have recently written a comprehensive review on modafinil’s complex and poorly understood pharmacology.”
MethodInfluentialHistamine H3 Receptor Antagonists Go to Clinics
Sander, K., Kottke, T., & Stark, H. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.2163 · Cited by 193
Modafinil Shifts Human Locus Coeruleus to Low-Tonic, High-Phasic Activity During Functional MRI
Minzenberg, M. J., Watrous, A. J., Yoon, J. H., Ursu, S., & Carter, C. S. (2008) · Science · doi:10.1126/science.1164908 · Cited by 188
Self-citationNon-pharmacological cognitive enhancement
Dresler, M., Sandberg, A., Ohla, K., Bublitz, C., Trenado, C., Mroczko-Wąsowicz, A., Kühn, S., & Repantis, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.002 · Cited by 180
“Although there is mounting evidence that the effects on dopamine and norepinephrine are primary, effects on gaminobutyric acid, glutamate, histamine and orexin/hypocretin are also theorized (Volkow et al., 2009; Minzenberg and Carter, 2008; Ballon and Feifel, 2006).”
BackgroundEvidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil
Zolkowska, D., Jain, R., Rothman, R. B., Partilla, J. S., Roth, B. L., Setola, V., Prisinzano, T. E., & Baumann, M. H. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146142 · Cited by 184
“In contrast, substantial evidence indicates that modafinil may exert its effects via presynaptic dopaminergic mechanisms (Nishino et al., 1998; Minzenberg and Carter, 2008).”
BackgroundG protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Wong, T., Li, G., Li, S., Gao, W., Chen, G., Gan, S., Zhang, M., Li, H., Wu, S., & Du, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01427-2 · Cited by 198
“Modafinil exhibits clinical efficacy in psychiatric conditions, including treatment-resistant depression and attention deficit/hyperactivity disorder.(375) Ozanimod, Siponimod, and Fingolimod are S1PR agonists that selectively bind to the S1PR1 and S1PR5 subtypes, inhibiting lymphocyte egress from lymph nodes.”
BackgroundAssessing cognitive function in clinical trials of schizophrenia
Barnett, J. H., Robbins, T. W., Leeson, V. C., Sahakian, B. J., Joyce, E. M., & Blackwell, A. D. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.01.012 · Cited by 174
“This important study has catalysed significant interest in the use of modafinil as an adjunctive treatment in schizophrenia (Minzenberg and Carter, 2008; Morein-Zamir et al., 2007).”
BackgroundPrefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
Brain Imaging Studies in Pathological Gambling
van Holst, R. J., van den Brink, W., Veltman, D. J., & Goudriaan, A. E. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0141-7 · Cited by 170
Becker, S. P., Willcutt, E. G., Leopold, D. R., Fredrick, J. W., Smith, Z. R., Jacobson, L. A., Burns, G. L., Mayes, S. D., Waschbusch, D. A., Froehlich, T. E., et al. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.07.821 · Cited by 175
Müller, U., Rowe, J. B., Rittman, T., Lewis, C., Robbins, T. W., & Sahakian, B. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.009 · Cited by 142
“, 2010; Mohamed and Sahakian, 2012) and in patients with neuropsychiatric disorders (Turner et al., 2004; Turner, 2006; Minzenberg and Carter, 2008).”
BackgroundCognition enhancers between treating and doping the mind
Lanni, C., Lenzken, S. C., Pascale, A., Del Vecchio, I., Racchi, M., Pistoia, F., & Govoni, S. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.02.004 · Cited by 166
“Its mechanisms is still poorly understood: modafinil has een postulated to exhibit effects on catecholamines, serotonin, lutamate, gamma amino-butyric acid, orexin, and histamine ystems in the brain [29].”
BackgroundGood night and good luck: Norepinephrine in sleep pharmacology
Mitchell, H. A., & Weinshenker, D. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.10.004 · Cited by 163
Castagné, V., Porsolt, R. D., & Moser, P. C. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.018 · Cited by 168
Spiller, H. A., Hays, H. L., & Aleguas, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0084-8 · Cited by 156
“Modafinil has been shown to potentiate norepinephrine neurotransmission and these effects appear to be responsible for the adrenergic receptor-mediated effects [89–91].”
BackgroundSleep Deprivation and the Epigenome
Gaine, M. E., Chatterjee, S., & Abel, T. G. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00014 · Cited by 172
“, 2009) and can improve cognitive function (Minzenberg and Carter, 2008).”
BackgroundWhat should we do about student use of cognitive enhancers? An analysis of current evidence
RAGAN, C. I., Bárd, I., & Singh, I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.016 · Cited by 170
Mereu, M., Bonci, A., Newman, A. H., & Tanda, G. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3232-4 · Cited by 148
“2009), direct inhibition of several neurotransmitter transporter systems that lead to increased monoamine transmission have been described (Minzenberg and Carter 2008).”
InfluentialCoccurello, R., & Moles, A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.008 · Cited by 163
Loland, C. J., Mereu, M., Okunola, O. M., Cao, J., Prisinzano, T. E., Mazier, S., Kopajtic, T., Shi, L., Katz, J. L., Tanda, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.022 · Cited by 144
McIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145
Neuropharmacology of Sleep and Wakefulness
Watson, C. J., Baghdoyan, H. A., & Lydic, R. (2010) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2010.08.003 · Cited by 134
Histamine H3Receptor as a Drug Discovery Target
Berlin, M. Y., Boyce, C. W., & Ruiz, M. D. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100064d · Cited by 142
How do the basal ganglia regulate sleep–wake behavior?
Lazarus, M., Huang, Z., Lu, J., Urade, Y., & Chen, J. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.07.001 · Cited by 146
Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., Taphoorn, M. J. B., Reijneveld, J. C., & Klein, M. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not102 · Cited by 134
α1-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition
Perez, D. M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.581098 · Cited by 130
“Modafini l i s a wake-promot ing non-amphetamine neurochemical with complex properties that can directly stimulate cortical catecholamine levels and indirectly stimulate serotonin along with other neurotransmitters (Minzenberg and Carter, 2008; Chen et al., 2013; Scoriels et al., 2013).”
BackgroundReith, M. E. A., Blough, B. E., Hong, W. C., Jones, K. T., Schmitt, K. C., Baumann, M. H., Partilla, J. S., Rothman, R. B., & Katz, J. L. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.12.005 · Cited by 136
Proost, M., Habay, J., Wachter, J. D., Pauw, K. D., Rattray, B., MEEUSEN, R. R., Roelands, B., & Cutsem, J. V. (2022) · Sports Medicine · doi:10.1007/s40279-022-01678-z · Cited by 149
“The pharmacological intervention modafinil is perhaps a logical one to combat MF given its action as a modulator of dopaminergic and adrenergic pathways [65, 79] (see Colzato and Mourits [80] for more information on the mechanisms of action of modafinil).”
BackgroundGoss, A. J., Kaser, M., Costafreda, S. G., Sahakian, B. J., & Fu, C. H. Y. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08560 · Cited by 133
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 146
“The wakefulness-promoting agent modafinil has indications for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder (Minzenberg and Carter, 2008; Myrick et al, 2004).”
BackgroundSpathis, A., Fife, K., Blackhall, F., Dutton, S., Bahadori, R., Wharton, R., O'Brien, M., Stone, P., Benepal, T., Bates, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.4346 · Cited by 125
“Compared with traditional stimulant drugs, such as methylphenidate, it has a relatively selective site of action in the brain, with fewer adverse effects and lower abuse potential.(6) JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T”
BackgroundThe likelihood of cognitive enhancement
LYNCH, G. S., Palmer, L. C., & Gall, C. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.024 · Cited by 134
“…(Beracochea et al., 2002) and humans (Turner et al., 2003; Baranski et al., 2004; Muller et al., 2004; Randall et al., 2005) is that they generally point to a drug influence on working memory as opposed to the encoding of long-term memory for specific information (Minzenberg and Carter, 2008).”
Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management
Fleming, B., Edison, P., & Kenny, L. M. (2023) · BMJ · doi:10.1136/bmj-2022-071726 · Cited by 142
Schmitt, K. C., & Reith, M. E. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025790 · Cited by 132
“Modafinil appears to lack many of the undesirable side effects of other stimulants, most notably: cardiovascular strain, sympathomimetic peripheral stimulation and significant addictive liability [11].”
Urban, K. R., & Gao, W. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00038 · Cited by 139
Bodenmann, S., Hohoff, C., Freitag, C., Deckert, J., Rétey, J. V., Bachmann, V, & Landolt, H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01689.x · Cited by 119
“This compound has no known affinity to adenosine A2A receptors (Minzenberg and Carter, 2008).”
BackgroundCarvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Measures to counteract the negative effects of night work
Pallesen, S., Bjorvatn, B., Magerøy, N., Saksvik, I. B., Waage, S., & Moen, B. E. (2010) · Scandinavian Journal of Work, Environment & Health · doi:10.5271/sjweh.2886 · Cited by 122
“It probably interacts with many wake- and sleep-promoting neurochemicals in the brain, such as dopamine, noradrenaline, serotonin, glutamate, gamma-aminobutyric acid (GABA), orexin, and histamine (131).”
BackgroundGhahremani, D. G., Tabibnia, G., Monterosso, J. R., Hellemann, G. S., Poldrack, R. A., & London, E. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.233 · Cited by 136
“…modafinil operating on multiple neurochemical systems in the brain, including those involving serotonin, glutamate, gamma aminobutyric acid, hypocretin/orexin, and histamine, its effects on catecholamines have been proposed to primarily underlie cognitive enhancement (Minzenberg and Carter, 2008).”
BackgroundInfluentialEffects of modafinil and methylphenidate on visual attention capacity: a TVA-based study
Finke, K., Dodds, C., Bublak, P., Regenthal, R., Baumann, F., Manly, T., & Müller, U. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1823-x · Cited by 135
“Methylphenidate and modafinil are two widely used psychostimulants that both exert their effects by enhancing the synaptic availability of the two catecholamines dopamine and noradrenaline (Berridge et al. 2006; Minzenberg and Carter 2008; Robbins and Arnsten 2009; Volkow et al. 2009).”
BackgroundFrontostriatal Circuits and the Development of Bulimia Nervosa
Berner, L. A., & Marsh, R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00395 · Cited by 107
“Pharmacological interventions such as Modafinil have been found to enhance PFC activation and improve cognitive control in both healthy adults and in psychiatric populations (e.g., individuals with schizophrenia; Minzenberg and Carter, 2007).”
BackgroundNeuroethical issues in cognitive enhancement
Sahakian, B. J., & Morein-Zamir, S. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106926 · Cited by 109
“In the case of modafinil (Provigil), despite considerable research its precise mechanism of action is unclear, although it has been found to exhibit a multitude of effects including potentiation of noradrenaline and, to a degree, dopamine neurotransmission (Volkow et al., 2009), elevation of extracellular glutamate, s…”
BackgroundMorgan, H. L., Petry, A. F., Licks, P. A. K., Ballester, A. O., Teixeira, K. N., & Dumith, S. C. (2017) · Revista Brasileira de Educação Médica · doi:10.1590/1981-52712015v41n1rb20160035 · Cited by 194
Pharmacological cognitive enhancement—how neuroscientific research could advance ethical debate
Maslen, H., Faulmüller, N., & Savulescu, J. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00107 · Cited by 92
“For example, although the way modafinil works is still unknown in detail (Minzenberg and Carter, 2008), neurologists do know that the brain of the narcoleptic is not neurophysiologically equivalent to the brain of the sleep-deprived individual and, correspondingly, it might be hypothesized that the…”
BackgroundZack, M., & Poulos, C. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108091072 · Cited by 103
“Specifically, modafinil enhances glutamate, norepinephrine, DA, serotonin, histamine, and orexin (Minzenberg and Carter, 2007).”
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
“Modafinil improves cognition in a variety of domains that are impaired in chronic MA users, including memory, attention, executive function, and cognitive control in healthy adults as well as patients with ADHD, depression, and schizophrenia (Minzenberg and Carter, 2008).”
BackgroundKutlubaev, M. A., Duncan, F. H., & Mead, G. E. (2012) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01618.x · Cited by 102
“Meanwhile, another study (57) found that patients with fatigue after brainstem ⁄diencephalic but not after cortical strokes responded to modafinil – psychostimulant, acting through catecholamines, serotonin, glutamate, gamma aminobutyric acid, orexin and histamine systems in the brain (58).”
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review
Veerman, S. R. T., Schulte, P. F. J., & de Haan, L. (2017) · Drugs · doi:10.1007/s40265-017-0789-y · Cited by 123
Goetghebeur, P., & Dias, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1132-9 · Cited by 113
Cognitive enhancers for the treatment of ADHD
Bidwell, L. C., McClernon, F. J., & Kollins, S. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.05.002 · Cited by 102
Franke, A. G., Gränsmark, P., Agricola, A., Schühle, K., Rommel, T., Sebastian, A., Balló, H. E., Gorbulev, S., Gerdes, C., Frank, B., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.01.006 · Cited by 111
Chemotherapy and Cognitive Impairment: Treatment Options
Fardell, J. E., Vardy, J. L., Johnston, I. N., & Winocur, G. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.112 · Cited by 114
Lazarus, M., Chen, J., Huang, Z., Urade, Y., & Fredholm, B. B. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_36 · Cited by 114
Pharmacological Cognitive Enhancement in Schizophrenia
Harvey, P. D. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9103-4 · Cited by 106
“Cognitive enhancement in healthy individuals is also reported with modafinil, but these improvements are much more substantial in individuals who are sleep deprived at baseline (Minzenberg and Carter 2008).”
Backgroundd’Angelo, C., Savulich, G., & Sahakian, B. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13813 · Cited by 108
“In addition to its primary effects on dopamine and noradrenaline, modafinil also modulates GABA, glutamate, 5-HT (serotonin), histamine and orexin (Minzenberg and Carter, 2007).”
BackgroundA behavioral neuroenergetics theory of ADHD
Killeen, P. R., Russell, V. A., & Sergeant, J. A. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.02.011 · Cited by 97
Wadhwa, M., Chauhan, G., Roy, K., Sahu, S., Deep, S., Jain, V., Kishore, K., Ray, K., Thakur, L., & Panjwani, U. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00049 · Cited by 99
“Concurrently, modafinil acts as a cognitive enhancer after directly binding to dopamine transporter and elevates the level of serotonin (Minzenberg and Carter, 2008; Rasetti et al., 2010).”
BackgroundDopamine transporter-related effects of modafinil in rhesus monkeys
Andersen, M. L., Kessler, E., Murnane, K. S., McClung, J. C., Tufik, S., & Howell, L. L. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1839-2 · Cited by 98
“For example, modafinil, a drug widely prescribed to treat narcolepsy and obstructive sleep apnea-associated somnolence (for review Minzenberg and Carter 2008) has been reported to selectively improve neuropsychological task performance in healthy volunteers (Turner et al. 2003), suggesting a…”
BackgroundModafinil treatment of fatigue in patients with ALS: A placebo‐controlled study
Rabkin, J. G., Gordon, P. H., McElhiney, M., Rabkin, R., Chew, S., & Mitsumoto, H. (2009) · Muscle & Nerve · doi:10.1002/mus.21245 · Cited by 91
“Time since diagnosis - months 19 (22)1 – 96 16 (18) 29 (33) t -1.”
An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil
Murillo-Rodríguez, E., Barciela Veras, A., Barbosa Rocha, N., Budde, H., & Machado, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00374 · Cited by 91
Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions
Wisor, J. P. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00139 · Cited by 102
Deflating the Neuroenhancement Bubble
Lucke, J. C., Bell, S., Partridge, B., & Hall, W. (2011) · AJOB Neuroscience · doi:10.1080/21507740.2011.611122 · Cited by 100
Sugden, C., Housden, C. R., Aggarwal, R., Sahakian, B. J., & Darzi, A. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182306c99 · Cited by 86
The Role of Sleep and the Effects of Sleep Loss on Cognitive, Affective, and Behavioral Processes
Hyndych, A., El-Abassi, R. N., & Mader, E. C. (2025) · Cureus · doi:10.7759/cureus.84232 · Cited by 145
“Minzenberg and Carter reviewed that modafinil enhances cognitive performance by modulating catecholaminergic and glutamatergic systems, with observed benefits in executive function, working memory, and attention in populations with narcolepsy, ADHD, and shift work disorder [58].”
Rodent models of insomnia: A review of experimental procedures that induce sleep disturbances
Revel, F. G., Gottowik, J., Gatti, S., Wettstein, J. G., & Moreau, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.03.002 · Cited by 98
Parallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction
Zack, M., & Poulos, C. (2009) · Current Drug Abuse Reviewse · doi:10.2174/1874473710902010011 · Cited by 86
“This may be due to its complex pharmacology, which includes activation of glutamate, norepinephrine, serotonin, histamine, and orexin in addition to DA [110].”
BackgroundPallier, P. N., & Morton, A. J. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.072 · Cited by 86
“In humans and in rodents, the cognitiveenhancing properties of Modafinil are well documented (for review, see Minzenberg and Carter, 2008).”
BackgroundAlzheimer's disease and age-related memory decline (preclinical)
Terry, A. V., Callahan, P. M., Hall, B., & Webster, S. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.002 · Cited by 86
“For example atomoxetine was observed to improve reversal learning in rats and monkeys (Seu et al., 2009) while modafinil has been overved to improve gognition in several domains including working memory and episodic memory in both rodent models and humans (reviewed, Minzenberg and Carter, 2008).”
BackgroundBodenmann, S., Xu, S., Luhmann, U., Arand, M., Berger, W., Jung, H., & Landolt, H. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.222 · Cited by 85
Bari, A., & Aston-Jones, G. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.020 · Cited by 85
“Other non-stimulant medications that have been shown to improve cognitive processes in both healthy and clinical subjects include the wake-promoting agent modafinil and NE reuptake inhibitors (Ballon and Feifel, 2006; Bidwell et al., 2011; Minzenberg and Carter, 2008).”
BackgroundEffects of Modafinil on Neural Correlates of Response Inhibition in Alcohol-Dependent Patients
Schmaal, L., Joos, L., Koeleman, M., Veltman, D. J., van den Brink, W., & Goudriaan, A. E. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.032 · Cited by 90
Cognitive enhancers in the treatment of substance use disorders: Clinical evidence
Brady, K. T., Gray, K. M., & Tolliver, B. K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.017 · Cited by 82
“Modafinil The non-amphetamine stimulant modafinil has received considerable attention as a potential psychotropic agent in several psychiatric disorders, including schizophrenia, ADHD, and more recently, cocaine and methamphetamine dependence (Ballon and Feifel, 2006; Minzenberg and Carter, 2008).”
BackgroundModulatory Effects of Modafinil on Neural Circuits Regulating Emotion and Cognition
Rasetti, R., Mattay, V. S., Stankevich, B., Skjei, K., Blasi, G., Sambataro, F., Arrillaga-Romany, I. C., Goldberg, T. E., Callicott, J. H., Apud, J. A., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.83 · Cited by 83
“…with animal and human behavioral data that showed an improvement with modafinil in performance in several domains of cognition including WM, recognition memory, sustained attention, and cognitive control (Minzenberg and Carter, 2008; Turner et al, 2003; Winder-Rhodes et al, 2010, in press).”
BackgroundInfluentialAction of Modafinil—Increased Motivation Via the Dopamine Transporter Inhibition and D1 Receptors?
Young, J. W., & Geyer, M. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.015 · Cited by 82
“The putative pro-cognitive effect of modafinil for treating neuropsychiatric disorders are of interest (1).”
BackgroundResultInfluential
Metadata
- Authors
- Minzenberg, M. J., & Carter, C. S.
- Affiliations
- University of California Davis Medical Center (US)
- Corresponding author
- Minzenberg, Michael J
- Venue
- Neuropsychopharmacology
- Published
- 2007-08-22
- Volume
- 33
- Issue
- 7
- Pages
- 1477-1502
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2122011624
- Semantic Scholar
- cf5b2a15296e7832bcfdd965f28583772ef2999c
- Cited by
- 713
- References
- 215
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 25 · 2023: 33 · 2022: 33 · 2021: 46 · 2020: 26 · 2019: 19 · 2018: 33 · 2017: 42 · 2016: 22 · 2015: 49 · 2014: 48 · 2013: 62 · 2012: 59
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 59883, MH066629, R01MH059883, R01MH066629)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Keywords
- modafinil, wakefulness-promoting agents, neurochemical mechanisms, cognition, catecholamines, serotonin, glutamate, GABA, orexin, histamine, working memory, episodic memory, prefrontal cortex, cognitive control, treatment-resistant depression, attention deficit hyperactivity disorder, schizophrenia, cognitive impairment, pharmacokinetics, abuse liability
- MeSH terms
- Modafinil, Animals, Mental Disorders, Benzhydryl Compounds, Brain Chemistry, Cognition, Humans, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.